Review Papers Claim by Claim

Visual summary — key reported formulation stability (selected datapoints)

Visualized evidence & immediate takeaways

• Lyophilization can materially improve thermostability. Multiple independent primary studies cited in the review report retention of physicochemical attributes and in vivo bioactivity for weeks–months or longer after freeze‑drying when appropriate cryoprotectants and buffers are used Khan et al. review summary
• Buffer choice matters: Tris or acetate/HEPES outperform PBS for lyophilization outcomes (less pH shift during freezing; better retention of encapsulation and activity) Khan et al. on buffers
• Not all lipids behave the same: primary studies show ionizable lipid identity and internal structure (core packing/pKa) strongly affect payload retention and post‑lyo biodistribution — meaning a given cryoprotectant may not rescue all LNP chemistries equally Lamoot et al. lipid-dependence data

Strengths of the review

1. Comprehensive collation of excipients, buffers, CPPs/CQAs, analytics, and reported stabilities from a broad recent literature base (references up to 2025) Khan et al. comprehensiveness
2. Clear, practical guidance: lists of candidate formulations (e.g., 10% sucrose + 5% trehalose in 10 mM Tris pH 7.4), typical CPP ranges, and CQAs useful for formulation teams and regulators Khan et al. practical guidance

Limitations, blindspots, and critical caveats

• Heterogeneous primary data: studies differ in LNP composition, mRNA cargo (size/payload), assay endpoints, storage definitions (RT vs 'ambient'), and animal models, limiting meta-analytic aggregation or quantitative generalization Khan et al. on heterogeneity
• Physicochemical vs biological endpoints: many reports rely on DLS/RiboGreen and short-term in vitro transfection; fewer studies measure robust in vivo immunogenicity over long storage periods. Thus physicochemical preservation does not guarantee preserved vaccine efficacy in humans TL-LNP primary study
• Regulatory and manufacturing gaps: the review states there is no FDA-specific lyophilization standard for mRNA-LNPs, and many industrial scale-up variables (vial geometry, fill volumes, continuous vs batch lyophilization) require further validation with QbD and digital twin approaches Khan et al. on regulatory gaps
• Potential biases: review depends on published positive‑result literature (publication bias), and many primary studies have small n (especially in vivo), short durations, and limited replication; these issues weaken confidence in uniformly optimistic storage claims Lamoot et al. sample-size caution

Actionable recommendations (from synthesis + critique)

1. Prioritize head‑to‑head studies that hold LNP composition constant and systematically vary cryoprotectant type/concentration and buffer, measuring both physicochemical CQAs and robust in vivo immunogenicity at clinically relevant antigens and dosing regimens (not only luciferase reporters) Khan et al. recommendations
2. Report standardized endpoints and minimal dataset: particle size/PDI (DLS), encapsulation (RiboGreen), capillary electrophoresis for intact mRNA, residual moisture (Karl‑Fischer), cryo‑TEM images, and at least one in vivo potency/immunogenicity readout for regulatory relevance.
3. Investigate lipid-specific failure modes — e.g., using SAXS/cryogenic imaging to relate core nanostructure and ionizable lipid pKa to susceptibility during freeze‑drying — then design lipid-tailored excipient strategies (internal trehalose loading, PEG-lipid tuning) Lamoot et al. SAXS mechanistic insight

What would disprove the paper's main practical claim?

Reproducible, blinded multi‑laboratory failures to maintain in vivo immunogenicity after lyophilization for formulations the review highlights as promising (e.g., 10% sucrose + 5% trehalose in Tris), across different mRNA antigens and at clinically relevant doses, would falsify the generality of the optimistic stability claims. Conversely, consistent replication of ≥12‑month 4 °C stability with retained immunogenicity across LNP chemistries would greatly strengthen the review's conclusion.

Concluding critical appraisal (brief)

The review is a timely, useful synthesis that organizes the field's rapidly growing experimental literature and gives practical starting points for formulation and process engineers; but downstream translational confidence requires standardized head‑to‑head experiments linking CQAs to immunogenicity and larger, blinded, multi-center replication studies before widespread regulatory acceptance.